Merck & Co., Inc. (MRK) Earnings History
8 quarters held2/6 transcripts analyzed3/40 figures attested
Connect your agentPeriodRevenueYoYNet incomeEPS (dil.)Filed
Q2 2026$16.6B+5.1%$-1.3B$-0.54Aug 4, 2026
Earnings call · Aug 4, 2026deck
| Q2 FY26 | YoY | 6M FY26 | |
|---|---|---|---|
| Revenue | $16.6B | +5.1% | $32.9B |
| Net income | $-1.3B | -130.2% | $-5.6B |
| Op income | – | – | – |
| EPS (dil.) | $-0.541 | -130.7% | – |
| EPS (basic) | – | – | – |
| Gross margin | 73.5% | -4.0pp | |
| Net margin | -8.0% | -36.0pp |
- [1] “GAAP) loss / earnings per share (EPS) assuming dilution was a loss per share of $0.54” view source
Guidance & outlook
Management guidance
Q2 2026fy_current
revenue
$66.3B—$67.3B
other
35—36
eps_diluted
$2.66—$2.76
Special items & operational metrics
Operational metrics
Q2 2026Animal Health
1775.0M
+7.8% YoY
Prior year: 1646.0M
USD Millions
KEYTRUDA/KEYTRUDA QLEX
8366.0M
+5.2% YoY
Prior year: 7956.0M
USD Millions
LIPFENDRA
N/A
USD Millions
WINREVAIR
588.0M
+75.0% YoY
Prior year: 336.0M
USD Millions
Q1 2026$16.3B+4.9%$-4.2B$-1.72Apr 30, 2026
| Q1 FY26 | YoY | |
|---|---|---|
| Revenue | $16.3B1 | +4.9% |
| Net income | $-4.2B | -183.5% |
| Op income | – | – |
| EPS (dil.) | $-1.72 | -185.6% |
| EPS (basic) | – | – |
| Gross margin | 74.2% | -3.8pp |
| Net margin | -26.0% | -58.7pp |
- [1] “Total Worldwide Sales Were $16.3 Billion (5% Growth; 3% Growth ex-FX)” view source
Q4 2025$16.4B+5.0%$3.0B$1.19Feb 3, 2026
| Q4 FY25 | YoY | FY25 | |
|---|---|---|---|
| Revenue | $16.4B | +5.0% | $65.0B |
| Net income | $3.0B | -20.8% | $18.3B |
| Op income | – | – | – |
| EPS (dil.) | $1.19 | -20.3% | – |
| EPS (basic) | – | – | – |
| Gross margin | 66.2% | -9.3pp | |
| Net margin | 18.1% | -5.9pp |
Q3 2025$17.3B+4.0%$5.8B$2.32Oct 30, 2025
| Q3 FY25 | YoY | 9M FY25 | |
|---|---|---|---|
| Revenue | $17.3B | +4.0% | – |
| Net income | $5.8B | +83.0% | $15.3B |
| Op income | – | – | – |
| EPS (dil.) | $2.32 | +87.0% | $6.08 |
| EPS (basic) | – | – | – |
| Gross margin | 77.7% | +2.2pp |
Q2 2025$15.8B-2.0%$4.4B$1.76Jul 29, 2025
| Q2 FY25 | YoY | 6M FY25 | |
|---|---|---|---|
| Revenue | $15.8B | -2.0% | – |
| Net income | $4.4B | -19.0% | $9.5B |
| Op income | – | – | – |
| EPS (dil.) | $1.76 | -17.8% | $3.77 |
| EPS (basic) | – | – | – |
| Gross margin | 77.5% | +0.7pp |
Q1 2025$15.5B-1.6%$5.1B$2.01Apr 24, 2025
| Q1 FY25 | YoY | |
|---|---|---|
| Revenue | $15.5B | -1.6% |
| Net income | $5.1B | +6.7% |
| Op income | – | – |
| EPS (dil.) | $2.01 | +7.5% |
| EPS (basic) | – | – |
| Gross margin | 78.0% | +0.4pp |
Q4 2024$15.6B+6.8%$3.7B$1.48Feb 4, 2025
| Q4 FY24 | YoY | FY24 | |
|---|---|---|---|
| Revenue | $15.6B | +6.8% | $64.2B |
| Net income | $3.7B | – | $17.1B |
| Op income | – | – | – |
| EPS (dil.) | $1.48 | – | $6.74 |
| EPS (basic) | – | – | – |
| Gross margin | 75.5% | +2.2pp |
Q3 2024$16.7B+4.4%$3.2B$1.24Oct 31, 2024
Earnings call · Oct 31, 2024
| Q3 FY24 | YoY | 9M FY24 | |
|---|---|---|---|
| Revenue | $16.7B1 | +4.4% | $48.5B |
| Net income | $3.2B | -33.5% | $13.4B |
| Op income | – | – | – |
| EPS (dil.) | $1.24 | -33.3% | $5.26 |
| EPS (basic) | – | – | – |
| Gross margin | 75.5% | +2.2pp | |
| Net margin | 18.9% | -10.8pp |
- [1] “Sales* 16,657 4” view source
Filing coverage
53 filings indexed · 102,244 XBRL facts| Filing | Date | Period | Sections | Tables |
|---|---|---|---|---|
| 10-Q | 2026-08-07 | – | 31 | 49 |
| 8-K | 2026-08-04 | – | 9 | 0 |
| 8-K | 2026-05-28 | – | 1 | 0 |
| 8-K | 2026-05-22 | – | 1 | 0 |
| 10-Q | 2026-05-04 | – | 30 | 55 |
| 8-K | 2026-04-30 | – | 9 | 0 |
| DEF 14A | 2026-04-08 | – | 20 | 0 |
| 10-K | 2026-02-24 | – | 54 | 90 |
| 8-K | 2026-02-03 | Q4 2025 | 7 | 0 |
| 8-K | 2025-12-04 | – | 2 | 0 |
Showing the latest 10 of 53 — the full set is in the API.